Literature DB >> 32253841

Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.

Lin Deng1,2, Ding-Qing Feng1, Bin Ling1,2.   

Abstract

OBJECTIVE: Drug-resistance and metastasis are major reasons for the high mortality of ovarian cancer (OC) patients. Cyclooxygenase-2 (COX-2) plays a critical role in OC development. This study was designed to evaluate the effects of COX-2 on migration and cisplatin (cis-dichloro diammine platinum, CDDP) resistance of OC cells and explore its related mechanisms.
METHODS: Cell counting kit-8 (CCK-8) assay was used to detect the cytotoxicity effects of celecoxib (CXB) and CDDP on SKOV3 and ES2 cells. The effect of COX-2 on migration was evaluated via the healing test. Western blot and real-time quantitative polymerase chain reaction (qPCR) were used to analyze E-cadherin, vimentin, Snail, and Slug levels.
RESULTS: COX-2 promoted drug-resistance and cell migration. CXB inhibited these effects. The combination of CDDP and CXB increased tumor cell sensitivity, reduced the amount of CDDP required, and shortened treatment administration time. COX-2 upregulation increased the expression of Snail and Slug, resulting in E-cadherin expression downregulation and vimentin upregulation.
CONCLUSIONS: COX-2 promotes cancer cell migration and CDDP resistance and may serve as a potential target for curing OC.

Entities:  

Keywords:  Ovarian cancer (OC); Cyclooxygenase-2 (COX-2); Drug resistance; Migration; Epithelial-mesenchymal transition (EMT)

Mesh:

Substances:

Year:  2020        PMID: 32253841      PMCID: PMC7183449          DOI: 10.1631/jzus.B1900445

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  41 in total

1.  Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas.

Authors:  Kazushi Shigemasa; Xiurong Tian; Lijun Gu; Yuko Shiroyama; Nobutaka Nagai; Koso Ohama
Journal:  Int J Oncol       Date:  2003-01       Impact factor: 5.650

2.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

3.  Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC.

Authors:  Xiaolu Zhai; Huijun Zhu; Wei Wang; Shu Zhang; Yixin Zhang; Guoxin Mao
Journal:  Med Oncol       Date:  2014-04-30       Impact factor: 3.064

4.  Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.

Authors:  Eun Yoon Cho; Yoonla Choi; Seoung Wan Chae; Jin Hee Sohn; Geung Hwan Ahn
Journal:  Pathol Int       Date:  2006-02       Impact factor: 2.534

5.  Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.

Authors:  Ling-Yen Chung; Shye-Jye Tang; Guang-Huan Sun; Teh-Ying Chou; Tien-Shun Yeh; Sung-Liang Yu; Kuang-Hui Sun
Journal:  Clin Cancer Res       Date:  2012-06-13       Impact factor: 12.531

6.  Possible regulatory role of Snail in NF-κB-mediated changes in E-cadherin in gastric cancer.

Authors:  Zenan Hu; Xiaojun Liu; Zhifeng Tang; Yongning Zhou; Liang Qiao
Journal:  Oncol Rep       Date:  2012-12-19       Impact factor: 3.906

7.  Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation.

Authors:  Juncheng Wei; Gang Xu; Mingfu Wu; Yongtao Zhang; Qiong Li; Ping Liu; Tao Zhu; Anping Song; Liangpin Zhao; Zhiqiang Han; Gang Chen; Shixuan Wang; Li Meng; Jianfeng Zhou; Yunping Lu; Shixuan Wang; Ding Ma
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

8.  Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies.

Authors:  Charles N Landen; Subbi P Mathur; Mary S Richardson; William T Creasman
Journal:  Am J Obstet Gynecol       Date:  2003-05       Impact factor: 8.661

Review 9.  Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.

Authors:  Kemal Kismet; M Turan Akay; Osman Abbasoglu; Aygün Ercan
Journal:  Cancer Detect Prev       Date:  2004

10.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

View more
  2 in total

1.  Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.

Authors:  Ya-Kun Liu; Ya-Jing Jia; Shi-Hao Liu; Hong-Jie Shi; Jing Ma
Journal:  Histol Histopathol       Date:  2021-02-11       Impact factor: 2.303

2.  Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT.

Authors:  Yuxin Qi; Wenping Yang; Shuang Liu; Fanjie Han; Haibin Wang; Yonghong Zhao; Yufa Zhou; Daijun Zhou
Journal:  Cancer Cell Int       Date:  2021-01-25       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.